PPIB and Alzheimer disease: The aim of this study was to confirm the β-amyloid hypothesis via analyzing the pharmacological properties of a 10-residue β-sheet breaker peptide H102 active in reducing amyloid load and cerebral damage in animal models of AD in an attempt to provide a firmly theoretical basis for the feasibility of H102 in the treatment of AD.